|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100048677 |
|
最近更新日期: Date of Last Refreshed on: |
2021-07-12 09:13:08 |
|
注册时间: Date of Registration: |
2021-07-12 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于家系单体型模型的胚胎遗传检测一体化新方法的建立及临床应用 |
|
Public title: |
The establishment and clinical application of integrated technology of embryos testing based on core family haplotype model |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于家系单体型模型的胚胎遗传检测一体化新方法的建立及临床应用 |
|
Scientific title: |
The establishment and clinical application of integrated technology of embryos testing based on core family haplotype model |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张硕 |
研究负责人: |
张硕 |
|
Applicant: |
Shuo Zhang |
Study leader: |
Shuo Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 13122363696 |
研究负责人电话:
Study leader's |
+86 13122363696 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
chnszhang@163.com |
研究负责人电子邮件: Study leader's E-mail: |
chnszhang@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市黄浦区方斜路419号 |
研究负责人通讯地址: |
上海市黄浦区方斜路419号 |
|
Applicant address: |
419 Fangxie Road, Shanghai, China |
Study leader's address: |
419 Fangxie Road, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
200011 |
研究负责人邮政编码: Study leader's postcode: |
200011 |
|
申请人所在单位: |
复旦大学附属妇产科医院 |
||
|
Applicant's institution: |
Obstetrics and Gynecology Hospital of Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属妇产科医院 |
||
|
Affiliation of the Leader: |
Obstetrics and Gynecology Hospital of Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
kyy-2020-182 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属妇产科医院伦理委员会 |
||
|
Name of the ethic committee: |
the Ethics Committee of the Obstetrics and Gynecology Hospital, Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-08-06 00:00:00 | ||
|
伦理委员会联系人: |
鞠丹丹 |
||
|
Contact Name of the ethic committee: |
Ju Dandan |
||
|
伦理委员会联系地址: |
上海市黄浦区方斜路566号 |
||
|
Contact Address of the ethic committee: |
566 Fangxie Road, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
复旦大学附属妇产科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Obstetrics and Gynecology Hospital, Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市黄浦区方斜路419号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
419 Fangxie Road, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市科委“科技创新行动计划”医学创新研究专项 (20Y11907200) |
||||||||||||||||||||||
|
Source(s) of funding: |
the Science and Technology Innovation Action Plan Program of Shanghai (20Y11907200) |
||||||||||||||||||||||
|
研究疾病: |
单基因病,染色体结构变异 |
||||||||||||||||||||||
|
Target disease: |
Single gene disease, chromosomal structure variation |
||||||||||||||||||||||
|
研究疾病代码: |
H0425 |
||||||||||||||||||||||
|
Target disease code: |
H0425 |
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
诊断试验新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
Diagnostic New Technique Clincal Study |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
(1)阐明以家系为基础的单体型模型在遗传病患者胚胎检测中的作用。(2)建立一种简便高效、一体化的通用检测系统,通过一次检测能同时分析出胚胎的致病基因、胚胎的染色体结构重排和染色体非整倍体异常,不需要再分别检测,且对不同的携带者具有通用性,并证明该技术的有效性和临床适应性。实现患者优生优育,阻断遗传性疾病,提高子代健康水平。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To clarify the role of family-based haplotype models in embryo detection of patients with genetic diseases. (2) Establishing a simple, efficient, and integrated universal detection system that can simultaneously analyze the gene variations, chromosome structure rearrangements and chromosomal aneuploidy abnormalities with a single test, without the need for separate detection. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)核型分析明确一方为染色体结构变异的夫妇,且夫妇双方同时携带有某致病基因(对于显性遗传病,一般夫妇一方为患者,另一方正常;对于隐性遗传病,一般夫妇双方同时为携带者;对于X连锁隐性遗传病,一般女方携带),同时抽取夫妇双方父母的外周血,对其分别进行致病基因突变和染色体核型分析,根据双方父母的检测结果明确该病例夫妇双方致病基因和染色体结构重排变异的来源。2)检测的胚胎为经过ICSI技术后获得的囊胚期胚胎。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) One partner is chromosomal structural variation carrier, and both couples carry a certain disease-causing gene at the same time (for dominant diseases, generally one of the couples is the patient and the other is normal; for recessive diseases, generally both couples are a carrier; for X-linked recessive diseases, generally carried by the woman).The peripheral blood of both parents of the couple will be drawn, and the gene mutation and chromosome karyotype analysis will be performed on them. 2) Embryos detected by PGH are obtained after ICSI. |
||||||||||||||||||||||
|
排除标准: |
1)有以下疾病史:甲状腺疾病史,肾上腺疾病史,性传播疾病史,精神心理障碍。 2) 具有以下子宫异常:子宫畸形(单角子宫、双子宫),未治疗的纵膈子宫、子宫腺肌瘤、黏膜下子宫肌瘤、子宫内膜息肉。 3) 存在辅助生殖技术及妊娠的禁忌证或患有对妊娠有明确影响的疾病:包括控制欠佳的I型、II型糖尿病;未明确诊断的肝肾疾病或肝肾功能不全;严重的贫血;深静脉血栓史、肺栓塞、心脑血管疾病;未控制的高血压,有明确症状的心脏疾病;可疑或明确肿瘤、未明确诊断的阴道流血。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) History of the following diseases: history of thyroid disease, history of adrenal gland disease, history of sexually transmitted diseases and mental disorders; 2) The following abnormalities of the uterus: uterine malformations (single angle uterus, double uterus), untreated mediastinal uterus, uterine adenomyoma, submucosal uterine fibroids, endometrial polyps; 3) Contraindications to assisted reproductive technology or diseases that have a clear impact on pregnancy: including poorly controlled type I, type 2 diabetes; undiagnosed liver or kidney disease or hepatorenal insufficiency; severe anemia History of deep venous thrombosis, pulmonary embolism, cardiovascular and cerebrovascular diseases, uncontrolled high blood pressure, heart disease, suspicious or unequivocal cancer and undiagnosed vaginal bleeding. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-08-01 00:00:00至 To 2023-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-08-01 00:00:00 至 To 2023-09-30 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
N/A |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
N/A |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
N/A |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表扫描件 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form scanning copy |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |